Overview

Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and evaluate the response of VB-111 on DTC.
Phase:
Phase 2
Details
Lead Sponsor:
Vascular Biogenics Ltd. operating as VBL Therapeutics